黑色素瘤的基因组特征及其治疗意义。
The Genomic Landscape of Melanoma and Its Therapeutic Implications.
机构信息
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Department of Dermatology, Pingtung Hospital, Ministry of Health and Welfare, Pingtung 900, Taiwan.
出版信息
Genes (Basel). 2023 Apr 29;14(5):1021. doi: 10.3390/genes14051021.
Abstract
Melanoma is one of the most aggressive malignancies of the skin. The genetic composition of melanoma is complex and varies among different subtypes. With the aid of recent technologies such as next generation sequencing and single-cell sequencing, our understanding of the genomic landscape of melanoma and its tumor microenvironment has become increasingly clear. These advances may provide explanation to the heterogenic treatment outcomes of melanoma patients under current therapeutic guidelines and provide further insights to the development of potential new therapeutic targets. Here, we provide a comprehensive review on the genetics related to melanoma tumorigenesis, metastasis, and prognosis. We also review the genetics affecting the melanoma tumor microenvironment and its relation to tumor progression and treatment.
摘要
黑色素瘤是皮肤最具侵袭性的恶性肿瘤之一。黑色素瘤的遗传组成复杂，不同亚型之间存在差异。借助于下一代测序和单细胞测序等新技术，我们对黑色素瘤的基因组景观及其肿瘤微环境的认识变得越来越清晰。这些进展可能解释了当前治疗指南下黑色素瘤患者治疗结果的异质性，并为潜在新治疗靶点的开发提供了更深入的见解。在这里，我们对与黑色素瘤发生、转移和预后相关的遗传学进行了全面的综述。我们还回顾了影响黑色素瘤肿瘤微环境的遗传学及其与肿瘤进展和治疗的关系。
相似文献
1
The Genomic Landscape of Melanoma and Its Therapeutic Implications.黑色素瘤的基因组特征及其治疗意义。
Genes (Basel). 2023 Apr 29;14(5):1021. doi: 10.3390/genes14051021.
2
The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma.长链非编码 RNA 在黑色素瘤肿瘤微环境和免疫治疗中的作用。
Front Immunol. 2022 Dec 19;13:1085766. doi: 10.3389/fimmu.2022.1085766. eCollection 2022.
3
Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.鉴定葡萄膜黑色素瘤的分子亚型系统和与免疫相关基因的四基因预后特征。
Exp Biol Med (Maywood). 2022 Feb;247(3):246-262. doi: 10.1177/15353702211053801. Epub 2021 Nov 7.
4
Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.肿瘤免疫微环境特征分析鉴定黑色素瘤的预后和免疫治疗相关基因特征。
Front Immunol. 2021 May 6;12:663495. doi: 10.3389/fimmu.2021.663495. eCollection 2021.
5
The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma.免疫相关基因的表达模式与肿瘤免疫微环境特征：预测皮肤黑色素瘤的预后和免疫治疗效果。
World J Surg Oncol. 2022 Sep 22;20(1):303. doi: 10.1186/s12957-022-02767-z.
6
Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.黑色素瘤进展至脑转移的表观基因组格局：未被探索的治疗选择。
Epigenomics. 2015;7(8):1303-11. doi: 10.2217/epi.15.77. Epub 2015 Dec 7.
7
Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.基于免疫基因集的皮肤黑色素瘤预后标志物的开发和验证。
Future Oncol. 2021 Nov;17(31):4115-4129. doi: 10.2217/fon-2021-0104. Epub 2021 Jul 22.
8
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy.高维单细胞转录组学在黑色素瘤和癌症免疫治疗中的应用。
Genes (Basel). 2021 Oct 16;12(10):1629. doi: 10.3390/genes12101629.
9
Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment.黑色素瘤微环境中的免疫细胞为预测复发风险和治疗反应提供了信息。
Expert Rev Mol Diagn. 2014 Jul;14(6):643-6. doi: 10.1586/14737159.2014.928206. Epub 2014 Jun 10.
10
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.泛癌种保守的微环境亚型可预测免疫治疗的反应。
Cancer Cell. 2021 Jun 14;39(6):845-865.e7. doi: 10.1016/j.ccell.2021.04.014. Epub 2021 May 20.
引用本文的文献
1
Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies.应对黑色素瘤放射抗性：机制与治疗策略
Cancers (Basel). 2025 Aug 14;17(16):2648. doi: 10.3390/cancers17162648.
2
Integrated spectroscopic and morphological analyses reveal cellular shifts in gene-silenced melanoma CSCs.综合光谱和形态学分析揭示了基因沉默的黑色素瘤癌症干细胞中的细胞变化。
Sci Rep. 2025 Aug 25;15(1):31175. doi: 10.1038/s41598-025-17155-2.
3
Mini review on skin biopsy: traditional and modern techniques.皮肤活检综述：传统与现代技术
Front Med (Lausanne). 2025 Mar 5;12:1476685. doi: 10.3389/fmed.2025.1476685. eCollection 2025.
4
Photocarcinogenesis of the skin: Current status and future trends.皮肤光致癌作用：现状与未来趋势
Kaohsiung J Med Sci. 2025 Apr;41(4):e12946. doi: 10.1002/kjm2.12946. Epub 2025 Feb 5.
5
Predicting Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis.使用神经网络分析预测皮肤黑色素瘤患者的突变
J Skin Cancer. 2024 Dec 19;2024:3690228. doi: 10.1155/jskc/3690228. eCollection 2024.
6
Braf-Mutant Melanomas: Biology and Therapy.BRAF 突变型黑色素瘤：生物学与治疗
Curr Oncol. 2024 Dec 3;31(12):7711-7737. doi: 10.3390/curroncol31120568.
7
An Extremely Rare Case of Primary Malignant Melanoma of the Kidney.一例极其罕见的原发性肾恶性黑色素瘤病例。
World J Oncol. 2024 Oct;15(5):837-843. doi: 10.14740/wjon1899. Epub 2024 Aug 10.
8
Advances in Personalized Oncology.个性化肿瘤学进展
Cancers (Basel). 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862.
9
Resolving Discrepancies in Idylla Mutational Assay Results Using Targeted Next-Generation Sequencing.采用靶向二代测序技术解决 Idylla 基因突变检测结果的差异。
Genes (Basel). 2024 Apr 23;15(5):527. doi: 10.3390/genes15050527.
10
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.黑色素瘤的分子前沿：发病机制、诊断及治疗进展
Int J Mol Sci. 2024 Mar 4;25(5):2984. doi: 10.3390/ijms25052984.
本文引用的文献
1
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.突变过程可预测转移性黑色素瘤免疫检查点抑制剂治疗的获益。
Nat Commun. 2022 Sep 19;13(1):5151. doi: 10.1038/s41467-022-32838-4.
2
Exploration and validation of metastasis-associated genes for skin cutaneous melanoma.皮肤黑色素瘤转移相关基因的探索和验证。
Sci Rep. 2022 Jul 29;12(1):13002. doi: 10.1038/s41598-022-17468-6.
3
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.瑞普替尼治疗 KIT 改变型转移性黑色素瘤患者的疗效和安全性。
ESMO Open. 2022 Aug;7(4):100520. doi: 10.1016/j.esmoop.2022.100520. Epub 2022 Jun 23.
4
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.2020 年全球皮肤黑色素瘤负担及 2040 年预测。
JAMA Dermatol. 2022 May 1;158(5):495-503. doi: 10.1001/jamadermatol.2022.0160.
5
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.Ribociclib 联合 Binimetinib 治疗NRAS 突变型黑色素瘤患者的 Ib/II 期临床试验。
Clin Cancer Res. 2022 Jul 15;28(14):3002-3010. doi: 10.1158/1078-0432.CCR-21-3872.
6
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.黑色素瘤的十年检查点阻断免疫治疗：了解免疫敏感性和耐药性的分子基础。
Nat Immunol. 2022 May;23(5):660-670. doi: 10.1038/s41590-022-01141-1. Epub 2022 Mar 3.
7
Identification of Potential Core Genes Between Primary and Metastatic Malignant Melanoma and Analysis of Their Immune Correlation.原发性和转移性恶性黑色素瘤潜在核心基因的鉴定及其免疫相关性分析
Int J Gen Med. 2022 Jan 11;15:379-391. doi: 10.2147/IJGM.S338890. eCollection 2022.
8
Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.家族性黑色素瘤与易感基因：最常见临床及皮肤镜表型、相关恶性肿瘤综述及管理实用技巧
J Clin Med. 2021 Aug 23;10(16):3760. doi: 10.3390/jcm10163760.
9
Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy.黏膜黑色素瘤：病理演变、通路依赖性与靶向治疗
Front Oncol. 2021 Jul 19;11:702287. doi: 10.3389/fonc.2021.702287. eCollection 2021.
10
NRAS mutant melanoma: Towards better therapies.NRAS 突变型黑色素瘤：迈向更好的治疗方法。
Cancer Treat Rev. 2021 Sep;99:102238. doi: 10.1016/j.ctrv.2021.102238. Epub 2021 May 29.
Zotero 插件